USPTO serial 98355762
ATOM-1
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- LAVOIE, RYAN CHRISTOPHER
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with ATOM-1?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $125
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
South San Francisco, CA, US
South San Francisco, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Aaron D. Hendelman
Aaron D. Hendelman Wilson Sonsini Goodrich & Rosati650 Page Mill RoadPalo Alto, CA 94304-1050United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Providing online non-downloadable computer software platforms for use in developing therapies for the modification of RNA expression and alteration of RNA translation, used in the treatment of cancers and autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; providing online non-downloadable computer software platforms for use in automated design and development of biomolecules for medical and scientific use, for use in the manufacture of biosensors, agriculture, synthetic biological research, laboratories and environmental safety and testing; providing online non-downloadable computer software platforms for use in drug design and development featuring machine-learning algorithms and lab automation tools; research and development of pharmaceuticals, namely, therapies for the modification of RNA expression and alteration of RNA translation, used in the treatment of cancers and autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; research and development in the fields of biotechnology, DNA, RNA, molecules and proteins; automated design and development of biomolecules for medical and scientific use, for use in the manufacture of biosensors, agriculture, synthetic biological research, laboratories and environmental safety and testing; drug design and development featuring machine-learning algorithms and lab automation tools; developing customized software in the field of drug design and development | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 13, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 12, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 12, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 12, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 15, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 5, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 4, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 4, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 8, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 8, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 8, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 7, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 12, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 17, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 17, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 28, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 15, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 12, 2024 | NWAP | NEW APPLICATION ENTERED | — |